Oncolytics After 2017 Refresh: New CEO Makes New Year Resolutions

2018 will be a year of change for Calgary, Canada-based Oncolytics Biotech, according to its CEO Dr. Matt Coffey. After switching gears to focus on metastatic breast cancer as the lead indication for its oncolytic virus-based drug candidate Reolysin, the biotech is ready to enter Phase III and step-up its clinical and commercial activities.

Oncolytics Biotech Inc., a Canadian firm developing an intravenous immuno-oncolytic virus agent against various cancers, is on a transformational path it hopes will lead the 1998-founded business towards a future as a leading immuno-oncology biotech.

In 2017, Oncolytics appointed new leadership members to its executive team and switched up its R&D focus from non-small cell lung cancer (NSCLC) to breast cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

02 May 2025

• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

02 May 2025

• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.